CDTX / Cidara Therapeutics, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36912 Cidara Therapeutics, Inc. (Exact name of registrant as specifi

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

SECOND AMENDED AND RESTATED CIDARA THERAPEUTICS, INC. a Delaware corporation (the “Corporation”) ARTICLE I REGISTERED OFFICE

EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF CIDARA THERAPEUTICS, INC. a Delaware corporation (the “Corporation”) ARTICLE I REGISTERED OFFICE Section 1. Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). ARTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 Cidara Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Cidara Therapeutics, Inc. (Name of Subject Co

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Cidara Therapeutics, Inc. (Name of Subject Company) Cidara Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities)

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

Merck to Complete Acquisition of Cidara Therapeutics

EX-99.(a)(5)(vi) Exhibit (a)(5)(vi) News Release Merck to Complete Acquisition of Cidara Therapeutics RAHWAY, N.J., January 7, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

POS AM As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CIDARA THERAPEUTICS, INC.

EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. FIRST: The name of the corporation is Cidara Therapeutics, Inc. (hereinafter, the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of i

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

As filed with the Securities and Exchange Commission on January 7, 2026

S-8 POS As filed with the Securities and Exchange Commission on January 7, 2026 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 3 CIDARA THERAPEUTICS, INC. (Name of Subject Company —

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 3 CIDARA THERAPEUTICS, INC. (Name of Subject Company — Issuer) CAYMUS PURCHASER, INC. (Offeror) A Wholly Owned Subsidiary of MERCK SHARP & DOHME LLC (Parent of Offeror) A Wholly Owned Subsidiary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Cidara Therapeutics, Inc. (Name of Subject Co

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Cidara Therapeutics, Inc. (Name of Subject Company) Cidara Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 CIDARA THERAPEUTICS, INC. (Name of Subject Company —

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 CIDARA THERAPEUTICS, INC. (Name of Subject Company — Issuer) CAYMUS PURCHASER, INC. (Offeror) A wholly owned subsidiary of MERCK SHARP & DOHME LLC (Parent of Offeror) A Wholly Owned Subsidiary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 CIDARA THERAPEUTICS, INC. (Name of Subject Company —

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 CIDARA THERAPEUTICS, INC. (Name of Subject Company — Issuer) CAYMUS PURCHASER, INC. (Offeror) A Wholly Owned Subsidiary of MERCK SHARP & DOHME LLC (Parent of Offeror) A Wholly Owned Subsidiary

Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock CIDARA THERAPEUTICS, INC. $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share CAYMUS PURCHASER, INC. a wholly owned subsi

EX-99.(a)(1)(i) Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock of CIDARA THERAPEUTICS, INC. at $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share by CAYMUS PURCHASER, INC. a wholly owned subsidiary of MERCK SHARP & DOHME LLC a wholly owned subsidiary of MERCK & CO., INC. THE OFFER AND WITHDRAWAL RI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CIDARA THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CAYMUS P

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CIDARA THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CAYMUS PURCHASER, INC. (Offeror) A Wholly Owned Subsidiary of MERCK SHARP & DOHME LLC (Parent of Offeror) A Wholly Owned Subsidiary of MERCK & CO., IN

TENDER AND SUPPORT AGREEMENT

EX-99.(d)(3) Exhibit (d)(3) TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 13, 2025, is by and among Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”), Caymus Purchaser, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned stockholder (“Stockholder”). WHEREAS, as of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 CIDARA THERAPEUTICS, INC. (Name of Subject Company) CIDARA THER

SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock and Series A Convertible Voting Preferred Stock CIDARA THERAPEUTICS, INC. $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated Decemb

EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock and Series A Convertible Voting Preferred Stock of CIDARA THERAPEUTICS, INC. at $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated December 5, 2025 by CAYMUS PURCHASER, INC. a wholly owned subsidiary of MERCK SHARP & DOHME LLC a wholly owned s

MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

EX-99.(e)(3) Exhibit (e)(3) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of the date of last signature below (the “Effective Date”), is entered into by and between Merck Sharp & Dohme LLC, having an address of 126 East Lincoln Avenue, Rahway, New Jersey 07065 USA (hereinafter referred to as “Merck”) and Cidara Therapeutics,

AGREEMENT AND PLAN OF MERGER CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025

EX-99.(d)(1) Exhibit (d)(1) Execution Version AGREEMENT AND PLAN OF MERGER among: CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 5 SECTION 2. MERGER TRANSACTION 6 2.1 Merger of Purchaser

LETTER OF TRANSMITTAL to Tender Shares of Common Stock and Series A Convertible Voting Preferred Stock CIDARA THERAPEUTICS, INC. $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated December 5, 20

EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock and Series A Convertible Voting Preferred Stock of CIDARA THERAPEUTICS, INC. at $221.50 Net Per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated December 5, 2025 by CAYMUS PURCHASER, INC. a wholly owned subsidiary of MERCK SHARP & DOHME LLC a wholly owned subsidiary

TENDER AND SUPPORT AGREEMENT

EX-99.(d)(4) Exhibit (d)(4) TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 13, 2025, is by and among Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”), Caymus Purchaser, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned stockholder (“Stockholder”). WHEREAS, as of

Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock Cidara Therapeutics, Inc. $221.50 Net per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated Dec

EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock of Cidara Therapeutics, Inc. at $221.50 Net per Common Share and $15,505.00 Net Per Series A Share Pursuant to the Offer to Purchase Dated December 5, 2025 by Caymus Purchaser, Inc. a whollv owned subsidiary off Merck Sharp & Dohme LLC a wholly owned

AGREEMENT AND PLAN OF MERGER CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025

EX-99.(e)(1) Exhibit (e)(1) Execution Version AGREEMENT AND PLAN OF MERGER among: CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 5 SECTION 2. MERGER TRANSACTION 6 2.1 Merger of Purchaser

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 9,250,347,814.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase dated December 5, 2025 and the related Letter of Transmi

EX-99.(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase dated December 5, 2025 and the related Letter of Transmittal and Notice of Guaranteed Delivery (each as defined below) and any amendments or supplements thereto and is be

Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock Cidara Therapeutics, Inc. $221.50 Net per Common Share and $15,505.00 Net per Series A Share Pursuant to the Offer to Purchase Dated Dec

EX-99.(a)(1)(v) Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock and Series A Convertible Voting Preferred Stock of Cidara Therapeutics, Inc. at $221.50 Net per Common Share and $15,505.00 Net per Series A Share Pursuant to the Offer to Purchase Dated December 5, 2025 by Caymus Purchaser, Inc. a wholly owned subsidiary of Merck Sharp & Dohme LLC a wholly owned su

MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

EX-99.(d)(2) Exhibit (d)(2) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of the date of last signature below (the “Effective Date”), is entered into by and between Merck Sharp & Dohme LLC, having an address of 126 East Lincoln Avenue, Rahway, New Jersey 07065 USA (hereinafter referred to as “Merck”) and Cidara Therapeutics,

Investigator Site Letter

EX-99.2 Exhibit 99.2 Investigator Site Letter To: All Cidara Investigator Sites From: Corrina Pavetto, Senior Vice President, Clinical Development Subject: Merck to Acquire Cidara Therapeutics Today, Cidara, the Sponsor of the Phase 3 ANCHOR trial, announced that we have entered into a definitive agreement to be acquired by Merck. A press release announcing the news is available here Merck to Acqu

AGREEMENT AND PLAN OF MERGER CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025

EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among: CIDARA THERAPEUTICS, INC., a Delaware corporation; MERCK SHARP & DOHME LLC, a New Jersey limited liability corporation; and CAYMUS PURCHASER, INC., a Delaware corporation Dated as of November 13, 2025 SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 5 SECTION 2. MERGER TRANSACTION 6 2.1 Merger of Purchaser into the

TENDER AND SUPPORT AGREEMENT

EX-10.1 Exhibit 10.1 Confidential TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 13, 2025, is by and among Merck Sharpe & Dohme LLC, a New Jersey limited liability company (“Parent”), Caymus Purchaser, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned stockholder (“Stockholder”). WHEREAS,

Employee Letter

EX-99.1 Exhibit 99.1 Employee Letter To: All Cidara Employees From: Jeff Stein, President & Chief Executive Officer Subject: Merck to Acquire Cidara Therapeutics in $9.2 Billion All-Cash Transaction All, I am excited to share transformational news for Cidara. This morning, we announced that we have entered into a definitive agreement to be acquired by Merck, through a subsidiary, for $221.50 per s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CIDARA THERAPEUTICS, INC. (Name of Subject Company — Issuer) CAYMUS P

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CIDARA THERAPEUTICS, INC. (Name of Subject Company — Issuer) CAYMUS PURCHASER, INC. a wholly owned subsidiary of MERCK SHARP & DOHME LLC (Names of Filing Persons — Offerors) Common Stock, par value $0.0001 per s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Cidara Therapeutics, Inc. (Name of Subject Company) Cidara Ther

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Cidara Therapeutics, Inc. (Name of Subject Company) Cidara Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (title of Class of Securities) 171757206 (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or other jurisdiction of incorporation) (Commis

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in ind

EX-99.1 Exhibit 99.1 News Release Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck’s science-led business development

LinkedIn Post

EX-99.4 Exhibit 99.4 LinkedIn Post We are excited to announce that we have agreed to be acquired by @Merck. This transaction represents an inflection point for Cidara and our efforts to revolutionize influenza prevention through our leading drug-Fc conjugate candidate, CD388. By combining our groundbreaking science with Merck’s global development, regulatory, and commercial capabilities, we will b

Partner / Key Vendor Letter

EX-99.3 Exhibit 99.3 Partner / Key Vendor Letter To: Partners / Key Vendors From: Subject: Merck to Acquire Cidara Therapeutics Today, we announced that we have entered into a definitive agreement to be acquired by Merck. A press release announcing the news is available here: Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent. As you are li

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in ind

EX-99.1 Exhibit 99.1 News Release Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck’s science-led business development

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Cidara Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AWARD CONTRACT 1. THIS CONTRACT IS RATED ORDER UNDER DPAS

exhibit1012025-09 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AWARD CONTRACT 1.

Press release issued November 6, 2025, reporting financial results for the third quarter ended September 30, 2025.

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results •Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic •Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Cidara Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2025 Cidara Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga

LETTER

September 4, 2025 Frank Karbe Chief Financial Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Dr. Suite 101 San Diego, CA 92121 Re: Cidara Therapeutics, Inc. Form 10-K for the period ended December 31, 2024 Filed March 6, 2025 File No. 001-36912 Dear Frank Karbe: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and a

*****

CORRESP August 26, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

LETTER

August 13, 2025 Frank Karbe Chief Financial Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Dr. Suite 101 San Diego, CA 92121 Re: Cidara Therapeutics, Inc. Form 10-K for the period ended December 31, 2024 Filed March 6, 2025 File No. 001-36912 Dear Frank Karbe: We have reviewed your filing and have the following comment(s). Please respond to this letter within ten business days by providing the

Filing Fee Table.

Calculation of Filing Fee Tables S-8 Cidara Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended (Common Stock, $0.0001 par value per share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Cidara Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

As filed with the Securities and Exchange Commission on August 7, 2025

As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results •Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups •End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA) •Closed upsized public offering for gross

Underwriting Agreement, dated June 24, 2025, by and among Cidara Therapeutics, Inc. and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein.

Exhibit 1.1 Cidara Therapeutics, Inc. 7,954,546 Shares of Common Stock Underwriting Agreement June 24, 2025 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Guggenheim Securities, LLC Cantor Fitzgerald & Co.  As Representatives of the   several Underwriters listed   in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585

Cidara Announces Pricing of Upsized Public Offering of Common Stock

EX-99.2 Exhibit 99.2 Cidara Announces Pricing of Upsized Public Offering of Common Stock San Diego, June 24, 2025 - Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price t

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Cidara Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Cidara Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Cidara Announces Proposed Public Offering of Common Stock San Diego, June 23, 2025 – Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250

7,954,546 Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-287104 Prospectus Supplement (To prospectus dated May 15, 2025) 7,954,546 Shares Common Stock We are offering 7,954,546 shares of our common stock at a purchase price of $44.00 per share. Our common stock is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CDTX.” On June 23, 2025, the last reported sale

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Cidara Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

NASDAQ: CDTX NAVIGATE Ph 2B June 23, 2025 JUNE 2025 2 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “estimate,” “plan”,

ex9912025-06x23 NASDAQ: CDTX NAVIGATE Ph 2B June 23, 2025 JUNE 2025 2 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

SUBJECT TO COMPLETION, DATED JUNE 23, 2025

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-287104 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 20, 2025).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat

Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended, Form of Grant Notice, Stock Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement thereunder

Exhibit 10.1 Cidara Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2024 Approved by the Stockholders: July 18, 2024 Amended by the Board of Directors: March 14, 2025 Approved by the Stockholders: June 18, 2025 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of 12:01 a.m. Pacific

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121

CORRESP Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn:  Doris Stacey Gama Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: May 8, 2025 File No.

LETTER

May 13, 2025 Jeffrey Stein Chief Executive Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121 Re: Cidara Therapeutics, Inc. Registration Statement on Form S-3 Filed May 8, 2025 File No. 333-287104 Dear Jeffrey Stein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding reque

, dated May 8, 2025, by and between Cidara Therapeutics, Inc. and Jefferies LLC

Exhibit 10.5 OPEN MARKET SALE AGREEMENTSM1 May 8, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.12 Exhibit 4.12 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] o

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cidara Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.11 Exhibit 4.11 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results •Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 •Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and

Form of Indenture, between the Registrant and one or more trustees to be named

EX-4.9 Exhibit 4.9 CIDARA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s C

As filed with the Securities and Exchange Commission on May 8, 2025

S-3 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cidara Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizatio

Employment offer letter between the Registrant and Nicole Davarpanah, M.D., J.D., dated April 25, 2025.

Exhibit 10.4 April 25, 2025 [BY EMAIL] Nicole Davarpanah, M.D., J.D. 14403 Marine Drive Silver Spring, MD 20905 Re: Employment Agreement Dear Nicole: This agreement (the “Agreement”) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the “Company”). This Agreement will become effective as of May 1, 2025, upon your acceptance by executing this Agreeme

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.13 Exhibit 4.13 CIDARA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CIDARA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

ARS

*#)
())( (*')(
#
-#
$""(($# ,1C89>7D?>

  $'"
 "1B;
$>5  ##*!
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*')(
-#
)
$
 ?B
D85
69C31<
I51B
5>454
535=25B

$'  )'#()$#
'%$')
%*'(*#)
)$
()$#

$'
4
$
)
(*' )(
-#
)
$

$'
)
)'#()$#
%'$
'$"





















)$




















?==9CC9?>
9<5

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

2020 Inducement Incentive Plan, as amended (incorporated by reference to Exhibit 10.7 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 6, 2025).

Exhibit 10.7 Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 Amended by the Compensation and Human Capital Committee of the Board of Directors: July 18, 2024 Amended by the Compensation and Human Capital Committee of the Board of Directors: February 12, 2025

As filed with the Securities and Exchange Commission on March 6, 2025

As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU

Insider Trading Policy of the Registrant.

Exhibit 19.1 CIDARA THERAPEUTICS, INC. INSIDER TRADING POLICY PERSONS COVERED This Insider Trading Policy of Cidara Therapeutics, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and its subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live i

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Non-Employee Director Compensation Policy, as amended.

Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 6, 2024 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe

Employment offer letter between the Registrant and Frank Karbe, dated February 14, 2025.

Exhibit 10.30 February 7, 2025 BY EMAIL Frank Karbe Mill Valley, CA Re: Employment Agreement Dear Frank: This agreement (the “Agreement”) sets forth the terms of your employment as the Chief Financial Officer of Cidara Therapeutics, Inc. (the “Company”). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. Upo

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results •Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial •Severe flu season enables potential mid-year assessment of efficacy •Closed $105.0 million financing with new and existing investors •Significantly expanded equity research coverage SAN DIEGO, March 6, 2025 — Cida

Description of the Registrant’s Securities.

Exhibit 4.5 DESCRIPTION OF COMMON STOCK General The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation, inc

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

Separation Agreement by and between the Registrant and Preetam Shah, dated February 14, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 18, 2025).

Exhibit 10.1 February 14, 2025 Preetam Shah, PhD, MBA VIA EMAIL/DOCUSIGN Dear Preetam: This letter sets forth the substance of the separation agreement (the “Agreement”) that Cidara Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be February 24, 2025 (the “Sep

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz

Separation Agreement by and between the Registrant and Taylor Sandison, dated January 7, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on January 7, 2025).

Exhibit 10.1 January 7, 2025 Taylor Sandison 1042 3rd Street, Encinitas, CA 92024 [email protected] VIA EMAIL/DOCUSIGN Dear Taylor: This letter sets forth the substance of the separation agreement (the “Agreement”) that Cidara Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your last day of work with the Company and your employment termination

Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2024

Exhibit 99.1 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2024 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe

7,041,309 shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284022 PROSPECTUS 7,041,309 shares of Common Stock This prospectus covers the offer and resale from time to time of up to an aggregate of 7,041,309 shares (the “Resale Shares”) of our common stock, par value $0.0001 per share (the “Common Stock”), of which 3,892,274 are issued and outstanding (the “Shares”) and 3,149,035 share

Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121

Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 December 30, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Cidara Therapeutics, Inc. (the “Company”)   Registration Statement on Form S-1   Filed: December 23, 2024   File No. 3

LETTER

December 30, 2024 Jeffrey Stein President and Chief Executive Officer Cidara Therapeutics, Inc.

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cidara Therapeutics, Inc.

As filed with the Securities and Exchange Commission on December 23, 2024 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CIDARA THERAPEUTI

Table of Contents As filed with the Securities and Exchange Commission on December 23, 2024 REGISTRATION NO.

CDTX / Cidara Therapeutics, Inc. / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 ea0224118-13gvivocidara.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event which Requires Filing of this Statement)

Joint Filing Statement

EX-99.1 2 ea022411801ex99-1cidara.htm JOINT FILING STATEMENT EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fili

CDTX / Cidara Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment

SC 13G 1 tm2430061d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement) Che

JOINT FILING AGREEMENT

EX-99.1 2 d837379dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that

CDTX / Cidara Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment

SC 13G 1 d837379dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of This Statement) Check

CDTX / Cidara Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 tm2429639d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, M

Securities Purchase Agreement, by and among the Registrant and the purchasers named therein, dated November 20, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 20, 2024, by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver

Form of Pre-Funded Warrant to Purchase Common Stock for Private Placement (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024).

Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN

Cidara Therapeutics Announces $105 Million Private Placement Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors

Exhibit 99.1 Cidara Therapeutics Announces $105 Million Private Placement Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors SAN DIEGO, November 21, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

Joint Filing Agreement

EX-1 2 tm2429639d1ex1.htm EXHIBIT 1 CUSIP No. 171757206 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 26, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Sec

Registration Rights Agreement, by and among the Registrant and the persons party thereto, dated November 20, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on November 26, 2024).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 20, 2024, is entered into by and among Cidara Therapeutics Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms

CDTX / Cidara Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 6 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga607422cdtx11142024.htm AMENDMENT NO. 6 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results SAN DIEGO, November 7, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious dise

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga

Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.

2020 Inducement Plan of the Registrant, as amended.

Exhibit 10.3 Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan Adopted by the Board of Directors: December 4, 2020 Amended by the Compensation Committee of the Board of Directors: August 16, 2021 Amended by the Compensation and Human Capital Committee of the Board of Directors: July 18, 2024 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under

As filed with the Securities and Exchange Commission on August 13, 2024

As filed with the Securities and Exchange Commission on August 13, 2024 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

License and Technology Agreement, by and between the Registrant and Janssen Pharmaceuticals, Inc., dated April 23, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 13, 2024).

Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version LICENSE AND TECHNOLOGY TRANSFER AGREEMENT between CIDARA THERAPEUTICS, INC. and JANSSEN PHARMACEUTICALS, INC. April 23, 2024 TABLE OF CONTENTS Page 1.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results SAN DIEGO, August 13, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious dise

16,800,000 shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280919 PROSPECTUS 16,800,000 shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 16,800,000 shares of our common stock. An aggregate of 240,000 shares of our Series A Convertible Voting Preferred Stock, par value $0.0001 per share

LETTER

July 29, 2024 Jeffrey Stein President and Chief Executive Officer Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121

Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 July 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 Filed: July 19, 2024 File No. 333-280919 Ladies a

POWER OF ATTORNEY

EX-24 2 d856817dex24.htm EX-24 Exhibit 24 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the signatu

Joint Filing Agreement

EX-99.1 3 d856817dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders

CDTX / Cidara Therapeutics, Inc. / Canaan XII L.P. - SC 13G Passive Investment

SC 13G 1 d856817dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CIDARA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 171757 20 6 (CUSIP Number) July 18, 2024 (Date of Event Which Requires Filing of this Statement) Check th

CDTX / Cidara Therapeutics, Inc. / BCLS Fund III Investments, LP - SC 13G Passive Investment

SC 13G 1 d868204dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par

CDTX / Cidara Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment

SC 13D 1 tm2420136d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Cidara Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 171757206 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cidara Therapeutics, Inc.

Power of Attorney. Reference is made to the signature page hereto.

S-1 Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 REGISTRATION NO.

2024 Equity Incentive Plan of the Registrant, Form of Grant Notice, Stock Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement Thereunder.

Exhibit 10.1 Cidara Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: May 22, 2024 Approved by the Stockholders: July 18, 2024 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of 12:01 a.m. Pacific Standard Time on the Effective Date, (i) no additional awards may be granted under the Prior

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on July 18, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

ARS

+$*
)**) )+(*)
$
.$
%##))%$ -3E:;@9FA@
 
 %(#
! #3D=
%@7  $$+"
(&%(*
&+()+$*
*%
)*%$

%(
6
%
*
)+(*)
.$
*
%
 AD
F:7
8;E53>
K73D
7@676
757?47D
 
 %(  *($)*%$
(&%(*
&+()+$*
*%
)*%$

%(
6
%
*
)+( *)
.$
*
%

%(
*
*($)*%$
&(%
(%#





















*%




















A??;E

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Cidara Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results SAN DIEGO, May 15, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Cidara Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizatio

1 Corporate Presentation: May 2024 NASDAQ: CDTX 2 Fo r w a rd - L o o k i n g S ta t e m e n t s T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i

corporatepresentation202 1 Corporate Presentation: May 2024 NASDAQ: CDTX 2 Fo r w a rd - L o o k i n g S ta t e m e n t s T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .

Assignment and Novation Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited.

Exhibit 2.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Assignment and Novation Agreement This Assignment and Novation agreement (“Agreement”) dated as of April 24, 2024 (the “Effective Date”), is entered into by and among CID

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorpo

Asset Purchase Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited.

Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT BY AND BETWEEN CIDARA THERAPEUTICS, INC. AND NAPP PHARMACEUTICAL GROUP LIMITED DATED AS OF 24 APRIL, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINI

First Amendment to Melinta License Agreement, dated April 23, 2024, by and between Melinta Therapeutics, LLC and Cidara Therapeutics, Inc.

Exhibit 2.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CIDARA THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment to the License Agreement (“Amendment”) is entered into and effective as of April 23, 2024 (the “Amendment Date”)

Securities Purchase Agreement, by and among Cidara Therapeutics, Inc. and the purchasers named therein.

Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 23, 2024, by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS

Form of Support Agreement.

Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of April 23, 2024, is made by and among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”) and the other persons and entities set forth on the signature pages hereto (the “Stockholders”). The Company and the Stockholders shall be referred to herein from time to time collectively as the “Parties.” Capi

Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on April 24, 2024).

Exhibit 3.1 EXECUTION VERSION CIDARA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “D

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

As filed with the Securities and Exchange Commission on April 22, 2024

As filed with the Securities and Exchange Commission on April 22, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy.

Exhibit 97.1 Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy adopted December 1, 2023 1.Introduction The Board of Directors (the “Board”) of Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the

Non-Employee Director Compensation Policy, as amended (incorporated by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K, filed on April 22, 2024).

Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 4, 2023 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe

Cidara Therapeutics Announces Reverse Stock Split

Exhibit 99.2 Cidara Therapeutics Announces Reverse Stock Split SAN DIEGO, April 22, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April 22, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on April 22, 2024).

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CIDARA THERAPEUTICS, INC. Cidara Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: First: The name of the Company is Cidara Therapeutics, Inc. The Company’s Certificat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Cidara Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Cidara Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36912 CUSIP NUMBER NOTIFICATION OF LATE FILING 171757107

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36912 CUSIP NUMBER NOTIFICATION OF LATE FILING 171757107 (Check one): ý Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

CDTX / Cidara Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

CDTX / Cidara Therapeutics, Inc. / Point72 Asset Management, L.P. - CIDARA THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

CDTX / Cidara Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 5 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga507422cdtx02142024.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Cidara Therapeutics, Inc. (Name of Issuer) Common Stock, par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Cidara Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Cidara Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, November 2, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Exhibit 99.1 Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1 •The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 •If approved by the European Medicines Agency, rezafungin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Cidara Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Cidara Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Orga

R&D Day SEPTEMBER 21, 2023 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words

R&D Day SEPTEMBER 21, 2023 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to

Exhibit 99.1 Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties SAN DIEGO, Sep

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results SAN DIEGO, August 3, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2023 and pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cidara Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

LETTER

United States securities and exchange commission logo July 24, 2023 Preetam Shah Chief Financial Officer Cidara Therapeutics, Inc.

July 7, 2023

July 7, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

LETTER

United States securities and exchange commission logo June 26, 2023 Preetam Shah Chief Financial Officer Cidara Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Cidara Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Year Ended December 31, 2021 (in thousands) Mundipharma Janssen Melinta Revenue from Collaboration and License Agreements: Point in Time: License of Intellectual Property – upon transfer of license $ — $ 27,000 $ — License of Intellectual Property –

May 31, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited)

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results SAN DIEGO, May 11, 2023 — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Seventh Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated April 20, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 11, 2023).

Exhibit 10.1 SEVENTH AMENDMENT TO LEASE DATED APRIL 20, 2023 Nancy Ridge Technology Center, L.P., a California limited partnership (“Lessor”), and Cidara Therapeutics, Inc., a Delaware corporation, (“Lessee”), hereby amend the Lease dated June 9, 2014 (as previously amended, the “Lease”), for Suites #101 through #105 at 6310 Nancy Ridge Drive, San Diego, CA 92121 (“Premises”) as follows: 1)Expirat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cidara Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizati

LETTER

United States securities and exchange commission logo April 28, 2023 Preetam Shah Chief Financial Officer Cidara Therapeutics, Inc.

ARS

' &
%&&% %'$&%
 
* 
!%%! ).?56:4@;:

  !$
 .>7
!:2   '
$"!$&
"'$%' &
&!
%&!

!$
 1
!
&
%'$&%
* 
&
!
 ;>
@52
36?0.8
E2.>
2:121
2029/2>

 !$  &$ %&!
$"!$&
"'$%' &
&!
%&!

!$
 1
!
&
%'$ &%
* 
&
!

!$
&
&$ %&!
"$!
$!





















&!




















;996??6;:

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Cidara Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organiza

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Cidara Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEU

As filed with the Securities and Exchange Commission on March 23, 2023

As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.

Non-Employee Director Compensation Policy, as amended.

Exhibit 10.5 Cidara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Approved by Board of Directors: December 5, 2022 Each member of the Cidara Therapeutics, Inc. Board of Directors (the “Board”) who is not also serving as an employee of Cidara Therapeutics, Inc. (“Cidara”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compe

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN DIEGO, March 23, 2023 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Cidara Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

Underwriting Agreement, dated March 3, 2023, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Common Stock).

EX-1.1 Exhibit 1.1 9,640,000 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENT March 3, 2023 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwrit

Underwriting Agreement, dated March 3, 2023, by and between Cidara Therapeutics, Inc. and Cantor Fitzgerald & Co. (Series X Convertible Preferred Stock)

EX-1.2 Exhibit 1.2 286,000 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENT March 3, 2023 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell t

286,000 Shares Series X Convertible Preferred Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 PROSPECTUS SUPPLEMENT (To Prospectus dated November 22, 2021) 286,000 Shares Series X Convertible Preferred Stock We are offering 286,000 shares of our Series X convertible preferred stock, or the Series X Preferred Stock (and the common stock issuable from time to time upon conversion of the Series X Preferred St

9,640,000 Shares Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 PROSPECTUS SUPPLEMENT (To Prospectus dated November 22, 2021) 9,640,000 Shares Common Stock We are offering 9,640,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “CDTX.” On March 3, 2023, the last reported sale price of our common stock on the Nasdaq Capital

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Cidara Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

SUBJECT TO COMPLETION, DATED MARCH 2, 2023

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

SUBJECT TO COMPLETION, DATED MARCH 2, 2023

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-260970 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Cidara Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

CDTX / Cidara Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Cidara Therapeutics, Inc. (Title of Class of Securities) Common Stock, par value $0.0

1

Exhibit 99.1 Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, February 14, 2023 – Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq Stock Market, LLC (“Na

CDTX / Cidara Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236168d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CIDARA THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 171757107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Cidara Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organ

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

CIDARA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited)

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results SAN DIEGO, November 3, 2022 — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2

Employment offer letter between the Registrant and Shane M. Ward, dated August 17, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022).

Exhibit 10.3 August 17, 2021 BY EMAIL Re: Employment Agreement Dear Shane: This agreement (the ?Agreement?) sets forth the terms of your continued employment as the Chief Legal Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. Upon commencement of your e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC.

Employment offer letter between the Registrant and Preetam Shah, dated August 19, 2021 (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022).

Exhibit 10.4 August 19, 2021 BY EMAIL Re: Employment Agreement Dear Preetam: This agreement (the ?Agreement?) sets forth the terms of your employment as the Chief Financial Officer and Chief Business Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. 1.Position. As t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Cidara Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Cidara Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36912 46-1537286 (State or Other Jurisdiction of Incorporation or Organi

Employment offer letter between the Registrant and Taylor Sandison, dated March 22, 2017 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, filed on November 3, 2022).

Exhibit 10.2 March 22, 2017 BY HAND DELIVERY AND EMAIL Taylor Sandison Re: Employment Agreement Dear Taylor: This letter (the ?Agreement?) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the ?Company?). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to Allison Lewis. As of